Cardiology Thought Leaders Make Predictions for New Oral Antithrombotics

Share Article

This new report from MedPredict provides in-depth qualitative insight into the rapidly evolving market for anticoagulant therapy, with a focus on antithrombotics.

According to this panel, whichever of the new oral antithrombotics wins for SPAF, also wins the majority of branded community use.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Antithrombotics,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the rapidly evolving market for oral antithrombotic therapy.

This new report captures the opinions of a panel of global experts who specialize in cardiology, cancer and surgery. The panel compares existing standards of care (warfarin, enoxaparin) with new oral anticoagulants Pradaxa (dabigatran), Xarelto (rivaroxaban) and Eliquis (apixaban), and next generation FXa molecules. The panel evaluated each molecule in relation to its potential for use in SPAF (stroke prevention in patients with atrial fibrillation), venous thromboembolism, pulmonary embolism, acute coronary syndrome, post-surgical prophylaxis and cancer. Cost of therapy and pharmacoeconomics were important consideration in this analysis.

“According to this panel, whichever of the new oral antithrombotics wins for SPAF, also wins the majority of branded community use,” says Dr. Jeffrey Berk, the report’s author. “SPAF is the largest indication by patient numbers, and in length of time patients remain on therapy. As the population ages, atrial fibrillation becomes more prevalent. Physicians are not going to want to have to deal with multiple oral antithrombotics. They will eventually narrow down to one or two rather than have a drug for each indication.”

The report also highlights the panel’s discussion related to the role of these new compounds in venous thromboembolism (VTE) prevention and treatment and acute coronary syndrome (ACS).

Companies/partnerships discussed in this report: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Momenta, Pfizer, Portola, Sanofi-Aventis, and The Medicines Company.    

The full report may be purchased by contacting MedPredict.

About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews
MedPredict
513.271.1924

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
Visit website